Trial Profile
A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary) ; Talimogene laherparepvec (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Liver metastases; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Amgen
- 13 Jan 2022 Status changed from active, no longer recruiting to completed.
- 02 Dec 2021 Planned End Date changed from 25 Aug 2022 to 4 Jan 2022.
- 26 Aug 2020 Planned End Date changed from 13 May 2022 to 25 Aug 2022.